Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 6/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397626 | 0.88 | NAMPT (0.42) | GPR119IDO1ESR2NAMPTUSP30 | |
| SCHEMBL30529609 | 0.84 | USP30 (0.43) | GPR119IDO1NAMPTUSP30FPR3 | |
| SCHEMBL21383778 | 0.84 | USP30 (0.43) | GPR119IDO1NAMPTUSP30FPR3 | |
| SCHEMBL29609272 | 0.84 | GPR119 (0.45) | GPR119NAMPT | |
| SCHEMBL24282932 | 0.84 | GPR119 (0.45) | GPR119NAMPT | |
| SCHEMBL22793059 | 0.81 | GPR119 (0.48) | GPR119NAMPTUSP30 | |
| SCHEMBL26310397 | 0.81 | GPR119 (0.39) | GPR119IDO1NAMPTUSP30FPR3 | |
| SCHEMBL30529378 | 0.81 | GPR119 (0.39) | GPR119IDO1NAMPTUSP30FPR3 | |
| SCHEMBL24335971 | 0.80 | HDAC2 (0.42) | GPR119NAMPT | |
| SCHEMBL30929782 | 0.78 | USP1 (0.43) | GPR119NAMPTUSP30NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | GPR119 2528/4885IDO1 4437/4885ESR2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.